Natural compounds for cancer treatment and prevention.

[1]  L. Wessjohann,et al.  First total synthesis of tubulysin B. , 2009, Organic letters.

[2]  P. Wong,et al.  Dual roles of Nrf2 in cancer. , 2008, Pharmacological research.

[3]  B. Frei,et al.  Vitamin C and cancer revisited , 2008, Proceedings of the National Academy of Sciences.

[4]  Mukul Sharma,et al.  Clinical status of anti-cancer agents derived from marine sources. , 2008, Anti-cancer agents in medicinal chemistry.

[5]  Donna D. Zhang,et al.  Nrf2 enhances resistance of cancer cells to chemotherapeutic drugs, the dark side of Nrf2. , 2008, Carcinogenesis.

[6]  Barbara McGrogan,et al.  Taxanes, microtubules and chemoresistant breast cancer. , 2008, Biochimica et biophysica acta.

[7]  I. Paterson,et al.  Development of practical syntheses of the marine anticancer agents discodermolide and dictyostatin. , 2008, Natural product reports.

[8]  L. Chow,et al.  Vinflunine: clinical perspectives of an emerging anticancer agent , 2008 .

[9]  B. Teicher.  Next generation topoisomerase I inhibitors: Rationale and biomarker strategies. , 2008, Biochemical pharmacology.

[10]  Zhiwei Wang,et al.  Efficacy of selected natural products as therapeutic agents against cancer. , 2008, Journal of natural products.

[11]  L. Kopelovich,et al.  Resveratrol: a review of preclinical studies for human cancer prevention. , 2007, Toxicology and applied pharmacology.

[12]  A. Murakami,et al.  Selective regulation of mutant K-ras mRNA expression by photo-cross-linking antisense oligonucleotide. , 2007, Nucleic Acids Symposium Series.

[13]  H. Mukhtar,et al.  Curcumin for chemoprevention of colon cancer. , 2007, Cancer letters.

[14]  M. Ratain,et al.  Rapamycin: Something Old, Something New, Sometimes Borrowed and Now Renewed , 2007, Clinical pharmacology and therapeutics.

[15]  N. Eskin,et al.  Novel mucilage fraction of Sinapis alba L. (mustard) reduces azoxymethane-induced colonic aberrant crypt foci formation in F344 and Zucker obese rats. , 2007, Phytomedicine : international journal of phytotherapy and phytopharmacology.

[16]  M. Fukuoka,et al.  Phase I study of TZT-1027, a novel synthetic dolastatin 10 derivative and inhibitor of tubulin polymerization, which was administered to patients with advanced solid tumors on days 1 and 8 in 3-week courses , 2007, Cancer Chemotherapy and Pharmacology.

[17]  D. Levêque,et al.  Molecular Pharmacokinetics of Catharanthus (Vinca) Alkaloids , 2007, Journal of clinical pharmacology.

[18]  H. Cortés-Funes,et al.  Role of anthracyclines in the era of targeted therapy , 2007, Cardiovascular Toxicology.

[19]  S. S. Kanwar,et al.  Pharmacological and clinical evaluation of L-asparaginase in the treatment of leukemia. , 2007, Critical reviews in oncology/hematology.

[20]  G. Giaccone,et al.  A phase I and pharmacokinetic study of LAF389 administered to patients with advanced cancer , 2007, Anti-cancer drugs.

[21]  Robert A Newman,et al.  Punica granatum (pomegranate) and its potential for prevention and treatment of inflammation and cancer. , 2007, Journal of ethnopharmacology.

[22]  Y. Pommier.  Topoisomerase I inhibitors: camptothecins and beyond , 2006, Nature Reviews Cancer.

[23]  E. Rowinsky,et al.  Novel agents that target tublin and related elements. , 2006, Seminars in oncology.

[24]  V. Rapozzi,et al.  Antisense locked nucleic acids efficiently suppress BCR/ABL and induce cell growth decline and apoptosis in leukemic cells , 2006, Molecular Cancer Therapeutics.

[25]  E. Mini,et al.  Pharmacological strategies for overcoming multidrug resistance. , 2006, Current drug targets.

[26]  R. Govindan,et al.  Novel formulations of taxanes: a review. Old wine in a new bottle? , 2006, Annals of oncology : official journal of the European Society for Medical Oncology.

[27]  B. Ramaswamy,et al.  Docetaxel: a tubulin-stabilizing agent approved for the management of several solid tumors. , 2006, Drugs of today.

[28]  A. Kong,et al.  Nrf2: a potential molecular target for cancer chemoprevention by natural compounds. , 2006, Antioxidants & redox signaling.

[29]  B. Mellado,et al.  A multicenter phase II study of the cryptophycin analog LY355703 in patients with platinum-resistant ovarian cancer , 2004, International Journal of Gynecologic Cancer.

[30]  J. Sussman,et al.  Inhibition of acetylcholinesterase by the anticancer prodrug CPT-11. , 2005, Chemico-biological interactions.

[31]  D. Scheinberg,et al.  Vitamin C antagonizes the cytotoxic effects of antineoplastic drugs. , 2005, Cancer research.

[32]  E. Vokes,et al.  Phase II trials of dolastatin-10 in advanced pancreaticobiliary cancers , 2005, Investigational New Drugs.

[33]  M. Diederich,et al.  Chemopreventive and therapeutic effects of curcumin. , 2005, Cancer letters.

[34]  E. Perez,et al.  Phase II trial of dolastatin-10 in patients with advanced breast cancer , 2005, Investigational New Drugs.

[35]  Y. Tripathi,et al.  Nutraceuticals and cancer management. , 2005, Frontiers in bioscience : a journal and virtual library.

[36]  William H Gerwick,et al.  Marine natural products as anticancer drugs. , 2005, Molecular cancer therapeutics.

[37]  O. S. Nielsen,et al.  Phase II study of ET-743 in advanced soft tissue sarcomas: a European Organisation for the Research and Treatment of Cancer (EORTC) soft tissue and bone sarcoma group trial. , 2005, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[38]  M. Blagosklonny.  Flavopiridol, An Inhibitor of Transcription: Implications, Problems and Solutions , 2004, Cell cycle.

[39]  D. Berry,et al.  Failure of higher-dose paclitaxel to improve outcome in patients with metastatic breast cancer: cancer and leukemia group B trial 9342. , 2004, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[40]  P. Duesberg,et al.  Aneuploidy Approaching a Perfect Score in Predicting and Preventing Cancer: Highlights from a Conference Held in Oakland, CA in January, 2004 , 2004, Cell cycle.

[41]  M. Jordan,et al.  Microtubules as a target for anticancer drugs , 2004, Nature Reviews Cancer.

[42]  N. Schiavone,et al.  Antisense oligonucleotide drug design. , 2004, Current pharmaceutical design.

[43]  Susan Band Horwitz,et al.  Mechanisms of Taxol resistance related to microtubules , 2003, Oncogene.

[44]  Y. Surh,et al.  Cancer chemoprevention with dietary phytochemicals , 2003, Nature Reviews Cancer.

[45]  C. Leonetti,et al.  The future of antisense therapy: combination with anticancer treatments , 2003, Oncogene.

[46]  Kiyoko Kato,et al.  Photodynamic antisense therapy: regulation of cervical carcinoma cells by psoralen-conjugated oligonucleotides. , 2003, Nucleic acids research. Supplement.

[47]  J. Verweij,et al.  Pharmacological Effects of Formulation Vehicles , 2003, Clinical pharmacokinetics.

[48]  J. Holden,et al.  The anti-neoplastic and novel topoisomerase II-mediated cytotoxicity of neoamphimedine, a marine pyridoacridine. , 2003, Biochemical pharmacology.

[49]  Paolo Vineis,et al.  Dietary fibre in food and protection against colorectal cancer in the European Prospective Investigation into Cancer and Nutrition (EPIC): an observational study , 2003, The Lancet.

[50]  S. Lentz,et al.  A phase II trial of dolastatin-10 in recurrent platinum-sensitive ovarian carcinoma: a Gynecologic Oncology Group study. , 2003, Gynecologic oncology.

[51]  G. Schwartz,et al.  Bryostatin-1: A Novel PKC Inhibitor in Clinical Development , 2003, Cancer investigation.

[52]  M. Villalona-Calero,et al.  Irinotecan: mechanisms of tumor resistance and novel strategies for modulating its activity. , 2002, Annals of oncology : official journal of the European Society for Medical Oncology.

[53]  T. Herzog.  Update on the role of topotecan in the treatment of recurrent ovarian cancer. , 2002, The oncologist.

[54]  T. Mekhail,et al.  Paclitaxel in cancer therapy , 2002, Expert opinion on pharmacotherapy.

[55]  J. Supko,et al.  Current perspectives on the clinical experience, pharmacology, and continued development of the camptothecins. , 2002, Clinical cancer research : an official journal of the American Association for Cancer Research.

[56]  G. Georg,et al.  The cryptophycins: Their synthesis and anticancer activity , 2002, Medicinal research reviews.

[57]  M. K. Harper,et al.  Aldisine alkaloids from the Philippine sponge Stylissa massa are potent inhibitors of mitogen-activated protein kinase kinase-1 (MEK-1). , 2002, Journal of medicinal chemistry.

[58]  Fikart I. Abdullaev.  Cancer Chemopreventive and Tumoricidal Properties of Saffron (Crocus sativus L.) , 2002, Experimental biology and medicine.

[59]  S. Thomas,et al.  Psoralen-modified clamp-forming antisense oligonucleotides reduce cellular c-Myc protein expression and B16-F0 proliferation. , 2001, Nucleic acids research.

[60]  L. D. Via,et al.  Photochemotherapy in the treatment of cancer. , 2001 .

[61]  T. Slaga,et al.  Avicins, a family of triterpenoid saponins from Acacia victoriae (Bentham), suppress H-ras mutations and aneuploidy in a murine skin carcinogenesis model , 2001, Proceedings of the National Academy of Sciences of the United States of America.

[62]  C. la Vecchia,et al.  Perspectives in cancer chemotherapy. , 2001, European journal of cancer.

[63]  J. Fahy.  Modifications in the "upper" velbenamine part of the Vinca alkaloids have major implications for tubulin interacting activities. , 2001, Current pharmaceutical design.

[64]  H. Wang.  Flavopiridol. National Cancer Institute. , 2001, Current opinion in investigational drugs.

[65]  B. Hill,et al.  Mechanism of mitotic block and inhibition of cell proliferation by the semisynthetic Vinca alkaloids vinorelbine and its newer derivative vinflunine. , 2001, Molecular pharmacology.

[66]  M. L. Quinn,et al.  Plants used against cancer - an extension of the work of Jonathan Hartwell. , 2000, Journal of ethnopharmacology.

[67]  R. James,et al.  Irinotecan combined with fluorouracil compared with fluorouracil alone as first-line treatment for metastatic colorectal cancer: a multicentre randomised trial , 2000, The Lancet.

[68]  A. Pardee,et al.  Release of Mitochondrial Cytochrome C in Both Apoptosis and Necrosis Induced by β-Lapachone in Human Carcinoma Cells , 1999, Molecular medicine.

[69]  G. Hortobagyi,et al.  A phase II study of docetaxel in patients with paclitaxel-resistant metastatic breast cancer. , 1998, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[70]  S. Steinberg,et al.  Phase I trial of continuous infusion flavopiridol, a novel cyclin-dependent kinase inhibitor, in patients with refractory neoplasms. , 1998, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[71]  B. Cheson,et al.  Clinical trials referral resource. Clinical trials of flavopiridol. , 1998, Oncology.

[72]  H. Malonne,et al.  DNA topoisomerase targeting drugs: mechanisms of action and perspectives. , 1997, Anti-cancer drugs.

[73]  R. Dorr.  Pharmacology of the Taxanes , 1997, Pharmacotherapy.

[74]  G. Núñez,et al.  Bcl-2 and Bcl-XL can differentially block chemotherapy-induced cell death. , 1997, Blood.

[75]  C. Croce,et al.  Bcl2 is the guardian of microtubule integrity. , 1997, Cancer research.

[76]  M. Gore,et al.  Topotecan, an active drug in the second-line treatment of epithelial ovarian cancer: results of a large European phase II study. , 1996, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[77]  S. Cole,et al.  Multidrug resistance mediated by the multidrug resistance protein (MRP) gene. , 1996, Biochemical pharmacology.

[78]  C. Borner,et al.  Bcl-2 interrupts the ceramide-mediated pathway of cell death. , 1996, Proceedings of the National Academy of Sciences of the United States of America.

[79]  H. Kantarjian,et al.  Treatment of Chronic Myelogenous Leukemia: Current Status and Investigational Options , 1996 .

[80]  J. Beijnen,et al.  Hypersensitivity Reactions to Etoposide , 1996, The Annals of pharmacotherapy.

[81]  R. Zittoun,et al.  Homoharringtonine: an effective new natural product in cancer chemotherapy. , 1995, Bulletin du cancer.

[82]  C. Hennequin,et al.  S-phase specificity of cell killing by docetaxel (Taxotere) in synchronised HeLa cells. , 1995, British Journal of Cancer.

[83]  P. Vrignaud,et al.  Preclinical evaluation of docetaxel (Taxotere). , 1995, Seminars in oncology.

[84]  I. Hickson,et al.  Structure and function of type II DNA topoisomerases. , 1994, The Biochemical journal.

[85]  W. Morison,et al.  Photochemotherapy beyond psoriasis. , 1994, Journal of the American Academy of Dermatology.

[86]  H. Hotani,et al.  Microtubule-stabilizing activity of microtubule-associated proteins (MAPs) is due to increase in frequency of rescue in dynamic instability: shortening length decreases with binding of MAPs onto microtubules. , 1994, Cell structure and function.

[87]  G. Cordell,et al.  Novel strategies for the discovery of plant-derived anticancer agents , 1994 .

[88]  Ronald J. Biediger,et al.  First total synthesis of taxol. 1. Functionalization of the B ring , 1994 .

[89]  D. Housman,et al.  p53-dependent apoptosis modulates the cytotoxicity of anticancer agents , 1993, Cell.

[90]  M. Hudson,et al.  Acute hypersensitivity reactions to etoposide in a VEPA regimen for Hodgkin's disease. , 1993, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[91]  A. Duncan,et al.  Overexpression of a transporter gene in a multidrug-resistant human lung cancer cell line. , 1992, Science.

[92]  Song Ji,et al.  From yew to us: the curious development of taxol. , 1991 .

[93]  K D Paull,et al.  Halichondrin B and homohalichondrin B, marine natural products binding in the vinca domain of tubulin. Discovery of tubulin-based mechanism of action by analysis of differential cytotoxicity data. , 1991, The Journal of biological chemistry.

[94]  I. Ringel,et al.  Studies with RP 56976 (taxotere): a semisynthetic analogue of taxol. , 1991, Journal of the National Cancer Institute.

[95]  F. Zunino,et al.  DNA topoisomerase II as the primary target of anti-tumor anthracyclines. , 1990, Anti-cancer drug design.

[96]  B. Cheson,et al.  Clinical trials referral resource. , 1990, Oncology.

[97]  B. Leyland-Jones,et al.  Hypersensitivity reactions from taxol. , 1990, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[98]  C. Nathan,et al.  Shared actions of endotoxin and taxol on TNF receptors and TNF release. , 1990, Science.

[99]  W. Malarkey,et al.  Antineoplastic properties of Maharishi-4 against DMBA-induced mammary tumors in rats , 1990, Pharmacology Biochemistry and Behavior.

[100]  B. Kennedy,et al.  Hypersensitivity Reactions to Etoposide A Case Report and Review of the Literature , 1988, American journal of clinical oncology.

[101]  R. Hertzberg,et al.  Camptothecin induces protein-linked DNA breaks via mammalian DNA topoisomerase I. , 1985, The Journal of biological chemistry.

[102]  L. Liu,et al.  Nonintercalative antitumor drugs interfere with the breakage-reunion reaction of mammalian DNA topoisomerase II. , 1984, The Journal of biological chemistry.

[103]  A. McPhail,et al.  Plant antitumor agents. VI. The isolation and structure of taxol, a novel antileukemic and antitumor agent from Taxus brevifolia. , 1971, Journal of the American Chemical Society.

[104]  A. McPhail,et al.  Plant Antitumor Agents. I. The Isolation and Structure of Camptothecin, a Novel Alkaloidal Leukemia and Tumor Inhibitor from Camptotheca acuminata1,2 , 1966 .

[105]  Keidan Se.  The chemotherapy of cancer in children. , 1966 .

[106]  R. Silvestrini,et al.  ‘Daunomycin’, a New Antibiotic of the Rhodomycin Group , 1964, Nature.

[107]  H. Spencer,et al.  Biological studies on stable and radioactive rare earth compounds. III. Distribution of radioactive yttrium in normal and ascites-tumor-bearing mice, and in cancer patients with serous effusions. , 1954, Journal of the National Cancer Institute.

[108]  J. G. Kidd.  REGRESSION OF TRANSPLANTED LYMPHOMAS INDUCED IN VIVO BY MEANS OF NORMAL GUINEA PIG SERUM , 1953, The Journal of experimental medicine.

[109]  J. G. Kidd.  REGRESSION OF TRANSPLANTED LYMPHOMAS INDUCED IN VIVO BY MEANS OF NORMAL GUINEA PIG SERUM , 1953, The Journal of experimental medicine.

[110]  Robert J. Feeney,et al.  CONTRIBUTIONS TO THE STUDY OF MARINE PRODUCTS. XXXII. THE NUCLEOSIDES OF SPONGES. I.1 , 1951 .

[111]  Robert J. Feeney,et al.  THE ISOLATION OF A NEW THYMINE PENTOSIDE FROM SPONGES1 , 1950 .

[112]  H. B. Woodruff,et al.  Actinomyces antibioticus, a New Soil Organism Antagonistic to Pathogenic and Non-pathogenic Bacteria , 1941, Journal of bacteriology.

[113]  Nicole G. Coufal,et al.  Anthracyclines and Anthracenediones , 2011 .

[114]  A. Hensel,et al.  Saffron in phytotherapy: Pharmacology and clinical uses , 2007, Wiener Medizinische Wochenschrift.

[115]  S. Keam,et al.  Trabectedin , 2012, Drugs.

[116]  A. Nakashima,et al.  Suppression of the mTOR-raptor signaling pathway by the inhibitor of heat shock protein 90 geldanamycin. , 2006, Journal of biochemistry.

[117]  H. Lipp,et al.  Camptothecin and Podophyllotoxin Derivatives , 2006, Drug safety.

[118]  T. Seki,et al.  Antithrombotic and anticancer effects of garlic‐derived sulfur compounds: A review , 2006, BioFactors.

[119]  H. McLeod,et al.  Cancer clinical pharmacology , 2005 .

[120]  J. Arnason,et al.  Natural health products and drug disposition. , 2005, Annual review of pharmacology and toxicology.

[121]  Rajgopal Govindarajan,et al.  Cancer--an ayurvedic perspective. , 2005, Pharmacological research.

[122]  P. Duesberg,et al.  Aneuploidy versus gene mutation as cause of cancer , 2001 .

[123]  R. Luduena.  Multiple forms of tubulin: different gene products and covalent modifications. , 1998, International review of cytology.

[124]  L. Neckers,et al.  The benzoquinone ansamycin 17-allylamino-17-demethoxygeldanamycin binds to HSP90 and shares important biologic activities with geldanamycin , 1998, Cancer Chemotherapy and Pharmacology.

[125]  E. Rowinsky.  The development and clinical utility of the taxane class of antimicrotubule chemotherapy agents. , 1997, Annual review of medicine.

[126]  W. Chan,et al.  Effects of BCR-ABL antisense oligonucleotides (AS-ODN) on human chronic myeloid leukemic cells: AS-ODN as effective purging agents. , 1995, Leukemia & lymphoma.

[127]  E. Rowinsky,et al.  Paclitaxel in cancer treatment , 1995 .

[128]  J. Burroughs,et al.  Overview of Taxol safety. , 1993, Journal of the National Cancer Institute. Monographs.

[129]  J. W. Wilson,et al.  Taxol: a history of pharmaceutical development and current pharmaceutical concerns. , 1993, Journal of the National Cancer Institute. Monographs.

[130]  J. Boehm,et al.  Synthesis of water-soluble (aminoalkyl)camptothecin analogs: inhibition of topoisomerase I and antitumor activity , 1991 .

[131]  B. Sinha.  Free radicals in anticancer drug pharmacology. , 1989, Chemico-biological interactions.

[132]  Douglas D. Smith.  History and chemistry , 1978 .

[133]  G. Alvernhe,et al.  Obtention d'amines primaires par action d'organo-magnesiens sur l'acetoxime , 1972 .

[134]  D. Weisleder,et al.  Structures of harringtonine, isoharringtonine, and homoharringtonine. , 1970, Tetrahedron letters.

[135]  F. Arcamone,et al.  Adriamycin (14-hydroxydaunomycin), a novel antitumor antibiotic. , 1969, Tetrahedron letters.

[136]  S. Farber,et al.  Advances in chemotherapy of cancer in man. , 1956, Advances in cancer research.